AES CORP. DL-,01/ US00130H1059 /
| 2024-05-31 5:13:46 PM | Chg. -0.247 | Volume | Bid5:21:56 PM | Ask5:21:56 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 19.828EUR | -1.23% | 689 Turnover: 13,940.133 |
19.852Bid Size: 503 | 19.870Ask Size: 503 | 14.11 bill.EUR | - | - |
GlobeNewswire
05-30
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
GlobeNewswire
05-28
Paperclip to Showcase SAFE® Searchable Encryption at Gartner Security & Risk Management Summit 2024
GlobeNewswire
05-28
Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 a...
GlobeNewswire
05-28
Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate...
GlobeNewswire
05-23
Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...
GlobeNewswire
05-23
Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-10...
GlobeNewswire
05-23
BioAtla Presenting Phase 1 Evalstotug Clinical Trial Data Demonstrating Clinical Benefit at the Upco...
GlobeNewswire
05-23
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrat...
GlobeNewswire
05-23
NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Adva...
GlobeNewswire
05-23
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term E...
GlobeNewswire
05-23
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 ...
GlobeNewswire
05-23
Tizona Therapeutics Presents Phase 1b TTX-080 Clinical Data in Advanced Colorectal Cancer and Head a...
GlobeNewswire
05-23
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epile...
GlobeNewswire
05-21
Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients w...
GlobeNewswire
05-21
InflaRx Presents New Analysis of PANAMO Phase III Trial in Severe COVID-19 at ATS 2024 Showing Poten...
GlobeNewswire
05-20
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire
05-20
Press Release: Dupixent® late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ...
GlobeNewswire
05-16
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lat...
GlobeNewswire
05-15
Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National ...
GlobeNewswire
05-15
Andes, HiRain, and HPMicro Join Hands to Build RISC-V AUTOSAR Software Ecosystem
GlobeNewswire
05-15
UPDATE - SPR® Therapeutics Announces Publication of Study Providing Evidence of the Impact of SPRINT...
